ArticleGenes & genomics2026
Prevalence of germline 113 cancer genes in healthy Indonesian hospital staff.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe absence of population-specific genetic variant frequency data in Indonesia complicates the interpretation of germline genetic variants of DNA repair genes critical for cancer predisposition.
objectiveto estimate baseline frequency of pathogenic/likely pathogenic germline variants (P/LP) and variant of unknown significance (VUS), we conducted an exploratory genetic screening in a convenience sample of 255 hospital staff without personal history of cancer, i.e. healthy subjects.
methodsA cross-sectional study was conducted at Dharmais Cancer Centre, Indonesia. 156 (61%) and 99 subjects (39%) reported absence and presence of family history (FH) of cancer, respectively. Peripheral blood DNA was sequenced using the Illumina 113-gene TruSight hereditary panel, and variants were classified according to the American College of Medical Genetics (ACMG) guidelines.
resultsTwelve out of 255 subjects or 4.71% (95% CI: 2.45–8.09%) carried P/LP variants of MUTYH, XPA, XPC, FANCA, FANCC, CHEK2 and Homologous DNA Repair (BRCA1, BRCA2, BRIP1, and RAD51D) genes. Five out of 99 with FH (5.1%) and seven out 156 subjects (4.48%) without FH had P/LP variants. There were 4 subjects (1.56%) harboring P/LP variants of BRCA1 (1.17%) and BRCA2 (0.39%) genes. BRCA1 and FANCA P/LP variants were found exclusively in 5 subjects with FH. One subject with FH carried dual P/LP variants of BRCA1 and CHEK2 genes. 21.6% subjects with and without family history had VUS in HRR genes.
conclusionsThe P/LP germline variants were detected in healthy subjects with and without family history. Furthermore, we detected several VUS that were potentially to be reclassified as benign since their prevalence in healthy subjects was more common than the rate of the disease.
Indexed as
Identifiers
41455088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.